Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
Somasundaram Gopalakrishnan
Advertisement
Somasundaram Gopalakrishnan, is senior consultant, Global Biopharm Center of Excellence, Merck Pte. Ltd.
Articles by Somasundaram Gopalakrishnan
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Advertisement
Latest Updated Articles
Review of SUT Adoption in Biopharma ManufacturingMarch 15th 2024
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
4
Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Trial
5